AstraZeneca signs first COVID-19 vaccine supply deal with Chinese company

Shenzhen Kangtai Biological Products will produce AstraZeneca Plc’s potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world’s most populous countries. To meet market demand in China, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, AstraZeneca said. It must have capacity to produce at least 200 million doses by the end of next year as part of the exclusive framework agreement, …read more

Source:: Yahoo Finance